Essential Medicines at the National Level : The Global Asthma Network's Essential Asthma Medicines Survey 2014

Show full item record



Permalink

http://hdl.handle.net/10138/300736

Citation

Bissell , K , Ellwood , P , Ellwood , E , Chiang , C-Y , Marks , G B , El Sony , A , Asher , I , Billo , N , Perrin , C , Global Asthma Network Study Grp & Mäkelä , M 2019 , ' Essential Medicines at the National Level : The Global Asthma Network's Essential Asthma Medicines Survey 2014 ' , International Journal of Environmental Research and Public Health , vol. 16 , no. 4 , 605 . https://doi.org/10.3390/ijerph16040605

Title: Essential Medicines at the National Level : The Global Asthma Network's Essential Asthma Medicines Survey 2014
Author: Bissell, Karen; Ellwood, Philippa; Ellwood, Eamon; Chiang, Chen-Yuan; Marks, Guy B.; El Sony, Asma; Asher, Innes; Billo, Nils; Perrin, Christophe; Global Asthma Network Study Grp; Mäkelä, M.
Contributor: University of Helsinki, Department of Dermatology, Allergology and Venereology
Date: 2019-02-02
Language: eng
Number of pages: 15
Belongs to series: International Journal of Environmental Research and Public Health
ISSN: 1660-4601
URI: http://hdl.handle.net/10138/300736
Abstract: Patients with asthma need uninterrupted supplies of affordable, quality-assured essential medicines. However, access in many low- and middle-income countries (LMICs) is limited. The World Health Organization (WHO) Non-Communicable Disease (NCD) Global Action Plan 2013-2020 sets an 80% target for essential NCD medicines' availability. Poor access is partly due to medicines not being included on the national Essential Medicines Lists (EML) and/or National Reimbursement Lists (NRL) which guide the provision of free/subsidised medicines. We aimed to determine how many countries have essential asthma medicines on their EML and NRL, which essential asthma medicines, and whether surveys might monitor progress. A cross-sectional survey in 2013-2015 of Global Asthma Network principal investigators generated 111/120 (93%) responses41 high-income countries and territories (HICs); 70 LMICs. Patients in HICs with NRL are best served (91% HICs included ICS (inhaled corticosteroids) and salbutamol). Patients in the 24 (34%) LMICs with no NRL and the 14 (30%) LMICs with an NRL, however no ICS are likely to have very poor access to affordable, quality-assured ICS. Many LMICs do not have essential asthma medicines on their EML or NRL. Technical guidance and advocacy for policy change is required. Improving access to these medicines will improve the health system's capacity to address NCDs.
Subject: essential medicines
access
noncommunicable diseases
asthma
inhaled corticosteroids
bronchodilators
national reimbursement list
NONCOMMUNICABLE DISEASES
LOW-INCOME
ACCESS
AVAILABILITY
CHALLENGES
3121 General medicine, internal medicine and other clinical medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
ijerph_16_00605_v2.pdf 322.0Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record